GRWD1

Summary

GRWD1 (glutamate rich WD repeat containing 1, HGNC:21270) is a protein-coding gene on chromosome 19q13.33, encoding Glutamate-rich WD repeat-containing protein 1 (Q9BQ67). Histone binding-protein that regulates chromatin dynamics and loading of minichromosome maintenance (MCM) complex at replication origins, possibly by promoting chromatin openness. It is a common-essential gene (DepMap: required in 92.5% of cancer cell lines).

This gene encodes a glutamate-rich protein that contains five WD-repeat motifs. The encoded protein may play a critical role in ribosome biogenesis and may also play a role in histone methylation through interactions with CUL4-DDB1 ubiquitin E3 ligase.

Source: NCBI Gene 83743 — RefSeq curated summary.

At a glance

• Gene–disease (curated): congenital diarrhea (Limited, GenCC)
• Clinical variants (ClinVar): 116 total — 2 likely-pathogenic
• Phenotypes (HPO): 4
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 92.5% of screened cell lines (common-essential)
• MANE Select transcript: NM_031485

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21270
Approved symbol	GRWD1
Name	glutamate rich WD repeat containing 1
Location	19q13.33
Locus type	gene with protein product
Status	Approved
Aliases	WDR28, GRWD, RRB1
Ensembl gene	ENSG00000105447
Ensembl biotype	protein_coding
OMIM	610597
Entrez	83743

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 3 protein_coding, 1 retained_intron

ENST00000253237, ENST00000598711, ENST00000599949, ENST00000928855

RefSeq mRNA: 1 — MANE Select: NM_031485 NM_031485

CCDS: CCDS12720

Canonical transcript exons

ENST00000253237 — 7 exons

Exon	Start	End
ENSE00000896536	48451034	48451231
ENSE00000896537	48450666	48450808
ENSE00000896542	48445983	48446192
ENSE00001249491	48452708	48457022
ENSE00002212624	48450313	48450526
ENSE00003485287	48446385	48446502
ENSE00003627273	48446681	48446843

Expression profiles

Bgee: expression breadth ubiquitous, 285 present calls, max score 88.53.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 29.1248 / max 205.5598, expressed in 1818 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
176787	24.9020	1814
176785	2.6609	1451
176786	1.5619	1042

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tongue squamous epithelium	UBERON:0006919	88.53	silver quality
gastrocnemius	UBERON:0001388	88.20	gold quality
muscle of leg	UBERON:0001383	87.36	gold quality
type B pancreatic cell	CL:0000169	85.75	silver quality
stromal cell of endometrium	CL:0002255	85.24	gold quality
skeletal muscle organ	UBERON:0014892	84.68	gold quality
muscle organ	UBERON:0001630	84.67	gold quality
olfactory bulb	UBERON:0002264	84.45	silver quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	84.17	gold quality
hindlimb stylopod muscle	UBERON:0004252	84.02	gold quality
esophagus mucosa	UBERON:0002469	83.79	gold quality
left uterine tube	UBERON:0001303	83.68	gold quality
skin of leg	UBERON:0001511	83.59	gold quality
apex of heart	UBERON:0002098	83.44	gold quality
granulocyte	CL:0000094	83.35	gold quality
body of stomach	UBERON:0001161	83.30	gold quality
right adrenal gland	UBERON:0001233	83.29	gold quality
skin of abdomen	UBERON:0001416	83.26	gold quality
left adrenal gland	UBERON:0001234	83.19	gold quality
pancreatic ductal cell	CL:0002079	83.17	silver quality
right coronary artery	UBERON:0001625	83.12	gold quality
ectocervix	UBERON:0012249	83.03	gold quality
lymph node	UBERON:0000029	82.99	gold quality
heart left ventricle	UBERON:0002084	82.96	gold quality
right adrenal gland cortex	UBERON:0035827	82.95	gold quality
hair follicle	UBERON:0002073	82.94	silver quality
vena cava	UBERON:0004087	82.91	silver quality
mucosa of transverse colon	UBERON:0004991	82.89	gold quality
esophagus	UBERON:0001043	82.86	gold quality
left adrenal gland cortex	UBERON:0035825	82.82	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GLI3

miRNA regulators (miRDB)

39 targeting GRWD1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-518D-5P	100.00	67.51	979
HSA-MIR-518E-5P	100.00	67.66	954
HSA-MIR-518F-5P	100.00	67.51	979
HSA-MIR-519A-5P	100.00	67.66	954
HSA-MIR-519B-5P	100.00	67.66	954
HSA-MIR-519C-5P	100.00	67.66	954
HSA-MIR-520C-5P	100.00	67.51	979
HSA-MIR-522-5P	100.00	67.66	954
HSA-MIR-523-5P	100.00	67.66	954
HSA-MIR-526A-5P	100.00	67.51	979
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-7112-5P	99.59	65.76	104
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-3123	99.47	67.15	2693
HSA-MIR-6828-5P	99.31	69.21	1433
HSA-MIR-3925-5P	99.21	67.90	1466
HSA-MIR-371A-5P	99.08	66.51	1914
HSA-MIR-4270	99.02	66.26	1987
HSA-MIR-330-5P	98.73	67.63	1788
HSA-MIR-7851-3P	98.72	64.88	980
HSA-MIR-6754-5P	98.60	65.54	1627
HSA-MIR-6776-5P	98.54	67.43	1304
HSA-MIR-326	98.25	66.44	1565
HSA-MIR-4717-5P	98.19	67.97	894
HSA-MIR-340-3P	98.11	68.25	679

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 92.5% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 6)

• Cdt1-binding protein GRWD1 promotes chromatin fluidity by influencing nucleosome structures, e.g., by transient eviction of H2A-H2B, and thereby promotes efficient MCM loading at replication origins. (PMID:27552915)
• GRWD1 overexpression in combination with HPV16 E7 and activated KRAS confers anchorage-independent growth and tumorigenic capacity on normal human fibroblasts. Consistent with this, GRWD1 overexpression is associated with poor prognosis in cancer patients. (PMID:27856536)
• findings suggest a novel oncogenic function of GRWD1 as a transcriptional regulator of p53 and that GRWD1 might be an attractive therapeutic target and prognostic marker in cancer therapy (PMID:31545368)
• GRWD1 promotes cell proliferation and migration in non-small cell lung cancer by activating the Notch pathway. (PMID:31891681)
• Comprehensive Analysis of Glutamate-Rich WD Repeat-Containing Protein 1 and Its Potential Clinical Significance for Pancancer. (PMID:34616846)
• GRWD1-WDR5-MLL2 Epigenetic Complex Mediates H3K4me3 Mark and Is Essential for Kaposi’s Sarcoma-Associated Herpesvirus-Induced Cellular Transformation. (PMID:34933446)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	grwd1	ENSDARG00000004806
mus_musculus	Grwd1	ENSMUSG00000053801
rattus_norvegicus	Grwd1	ENSRNOG00000021058
drosophila_melanogaster	l(2)09851	FBGN0022288
caenorhabditis_elegans		WBGENE00021899

Paralogs (9): ERCC8 (ENSG00000049167), GEMIN5 (ENSG00000082516), RBBP7 (ENSG00000102054), WDR59 (ENSG00000103091), PEX7 (ENSG00000112357), WDR77 (ENSG00000116455), WDR24 (ENSG00000127580), RBBP4 (ENSG00000162521), WDR73 (ENSG00000177082)

Protein

Protein identifiers

Glutamate-rich WD repeat-containing protein 1 — Q9BQ67 (reviewed: Q9BQ67)

All UniProt accessions (2): Q9BQ67, M0QX71

UniProt curated annotations — full annotation on UniProt →

Function. Histone binding-protein that regulates chromatin dynamics and loading of minichromosome maintenance (MCM) complex at replication origins, possibly by promoting chromatin openness. Plays a role in ribosomal biogenesis.

Subunit / interactions. Interacts with pre-ribosomal ribonucleoprotein complexes. Interacts with METTL18. Interacts with CDT1; origin binding of GRWD1 is dependent on CDT1. Interacts with CDC6; origin binding of GRWD1 is dependent on CDC6. Interacts with RPL3. Binds to histone H2A-H2B and H3-H4 complexes.

Subcellular location. Nucleus. Nucleolus. Chromosome.

Tissue specificity. Widely expressed.

Disease relevance. Diarrhea 14, congenital (DIAR14) [MIM:621160] An autosomal recessive disorder characterized by diarrhea manifesting within the first year of life, and diffuse arterial hypoplasia. The disease is caused by variants affecting the gene represented in this entry.

Induction. Induced by E2F transcription factors.

RefSeq proteins (1): NP_113673* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001680	WD40_rpt	Repeat
IPR015943	WD40/YVTN_repeat-like_dom_sf	Homologous_superfamily
IPR019775	WD40_repeat_CS	Conserved_site
IPR020472	WD40_PAC1	Repeat
IPR022052	Histone-bd_RBBP4-like_N	Domain
IPR036322	WD40_repeat_dom_sf	Homologous_superfamily
IPR051972	Glutamate-rich_WD_repeat	Family

Pfam: PF00400, PF12265

UniProt features (18 total): repeat 7, modified residue 4, sequence variant 3, region of interest 2, chain 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BQ67-F1	89.21	0.77

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 10, 119, 122, 344

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 165 (showing top): RRAGTTGT_UNKNOWN, GOBP_RIBOSOME_BIOGENESIS, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_10, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, AACWWCAANK_UNKNOWN, OCT1_03, WTGAAAT_UNKNOWN, BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_UP, FISCHER_DREAM_TARGETS, RFX1_02, GOBP_PROTEIN_DNA_COMPLEX_ORGANIZATION, HAN_SATB1_TARGETS_DN, GOBP_CHROMATIN_REMODELING, BURTON_ADIPOGENESIS_2, HAMAI_APOPTOSIS_VIA_TRAIL_DN

GO Biological Process (4): DNA replication (GO:0006260), nucleosome assembly (GO:0006334), nucleosome disassembly (GO:0006337), ribosome biogenesis (GO:0042254)

GO Molecular Function (5): chromatin binding (GO:0003682), DNA replication origin binding (GO:0003688), RNA binding (GO:0003723), histone binding (GO:0042393), protein binding (GO:0005515)

GO Cellular Component (6): nucleus (GO:0005634), nucleoplasm (GO:0005654), chromosome (GO:0005694), nucleolus (GO:0005730), cytosol (GO:0005829), protein-containing complex (GO:0032991)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
nucleosome organization	2
binding	2
nuclear lumen	2
cellular anatomical structure	2
intracellular membraneless organelle	2
DNA metabolic process	1
DNA biosynthetic process	1
chromatin organization	1
protein-DNA complex assembly	1
protein-DNA complex disassembly	1
ribonucleoprotein complex biogenesis	1
sequence-specific double-stranded DNA binding	1
nucleic acid binding	1
protein binding	1
intracellular membrane-bounded organelle	1
cytoplasm	1
cellular_component	1

Protein interactions and networks

STRING

2374 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GRWD1	RPL3	P39023	952
GRWD1	BOP1	Q14137	945
GRWD1	CDT1	Q9H211	935
GRWD1	TSR2	Q969E8	776
GRWD1	RPL11	P25121	753
GRWD1	HEATR3	Q7Z4Q2	736
GRWD1	DCAF5	Q96JK2	599
GRWD1	SURF6	O75683	574
GRWD1	RPL5	P46777	545
GRWD1	ORC6	Q9Y5N6	534
GRWD1	METTL18	O95568	509
GRWD1	COPS7A	Q9UBW8	508
GRWD1	BCCIP	Q9P287	486
GRWD1	PPM1G	O15355	471
GRWD1	DDB1	Q16531	471

IntAct

89 interactions, top by confidence:

A	B	Type	Score
DTL	DDB1	psi-mi:“MI:0914”(association)	0.740
CUL4B	CUL4A	psi-mi:“MI:0914”(association)	0.730
SPTLC1	SPTLC2	psi-mi:“MI:0914”(association)	0.680
SEC13	SEC16A	psi-mi:“MI:0914”(association)	0.640
CUL4B	EED	psi-mi:“MI:0914”(association)	0.560
COP1	DDB1	psi-mi:“MI:0914”(association)	0.530
TNFAIP3	LRRIQ3	psi-mi:“MI:2364”(proximity)	0.420
SDC1	ILVBL	psi-mi:“MI:0915”(physical association)	0.400
JUN		psi-mi:“MI:0914”(association)	0.350
JUN	TPM3	psi-mi:“MI:0914”(association)	0.350
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
CUL4B	TLE1	psi-mi:“MI:0914”(association)	0.350
SNRNP40	WDR5	psi-mi:“MI:0914”(association)	0.350
WDR26	DDB1	psi-mi:“MI:0914”(association)	0.350
WDR5B	DDB1	psi-mi:“MI:0914”(association)	0.350
WDR5	DDB1	psi-mi:“MI:0914”(association)	0.350
PPM1G	HADHA	psi-mi:“MI:0914”(association)	0.350
RRP1B	ZNF785	psi-mi:“MI:0914”(association)	0.350
		psi-mi:“MI:0914”(association)	0.350
NUDCD1	TUBAL3	psi-mi:“MI:0914”(association)	0.350
Prdm16	ESYT2	psi-mi:“MI:0914”(association)	0.350
Mecom	ESYT2	psi-mi:“MI:0914”(association)	0.350
ESR1	ESYT2	psi-mi:“MI:0914”(association)	0.350
CAND1	GTPBP10	psi-mi:“MI:0914”(association)	0.350
CUL1	LGALS8	psi-mi:“MI:0914”(association)	0.350
COPS5	FBLL1	psi-mi:“MI:0914”(association)	0.350

BioGRID (602): GRWD1 (Affinity Capture-RNA), GRWD1 (Affinity Capture-RNA), GRWD1 (Reconstituted Complex), GRWD1 (Co-fractionation), GRWD1 (Co-fractionation), GRWD1 (Co-fractionation), GRWD1 (Co-fractionation), GRWD1 (Co-fractionation), GRWD1 (Co-fractionation), GRWD1 (Co-fractionation), GRWD1 (Co-fractionation), NOC2L (Co-fractionation), POLR1E (Co-fractionation), RBM19 (Co-fractionation), GRWD1 (Affinity Capture-MS)

ESM2 similar proteins: A1L112, A4IHS2, A8NZM5, B2ZZS9, O00423, O80775, O95834, P93107, P97452, Q05BC3, Q0DYP5, Q13216, Q13610, Q13685, Q15269, Q1JQD2, Q2HJ56, Q32KQ2, Q32P44, Q3SZK1, Q4V8C3, Q562C2, Q58DT8, Q5BIM8, Q5F3K4, Q5R9T6, Q5RCG7, Q5RFQ3, Q5VU92, Q5XI13, Q5ZK69, Q6DRF9, Q6P6T4, Q6PFM9, Q7TNG5, Q7YR70, Q810D6, Q8BH57, Q8BHB4, Q8BU03

Diamond homologs: A1CH75, A1CXL0, A2QI22, A3LQ86, A4R2Q6, A5DL92, A5DST9, A6R3K5, A6S0T8, A6ZPA9, A7ECP3, A7TMF9, A8IR43, B0Y5V6, B2B5V0, B2VZH2, B3RQN1, G0SFB5, O74184, P41318, P61480, Q0CLJ4, Q0UXP3, Q12024, Q1DJF7, Q1JQD2, Q2GXT0, Q2T9T9, Q2UGK1, Q4WP10, Q5APF0, Q5B4R1, Q5BJ90, Q5XI13, Q5XUX1, Q5ZJW8, Q6BLS5, Q6CEW7, Q6CU59, Q6FKK3

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 123 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Signaling by ALK fusions and activated point mutants	7	12.7×	9e-04
Neddylation	10	5.7×	3e-03

GO biological processes:

GO term	Partners	Fold	FDR
cell surface receptor protein tyrosine kinase signaling pathway	8	13.5×	1e-04
ribosomal small subunit biogenesis	5	11.1×	7e-03
insulin receptor signaling pathway	5	10.8×	7e-03
positive regulation of protein catabolic process	5	9.9×	1e-02
regulation of cell cycle	8	5.8×	7e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

116 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	2
Uncertain significance	91
Likely benign	11
Benign	2

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
3252071	NM_031485.4(GRWD1):c.920A>G (p.His307Arg)	Likely pathogenic
3252072	NM_031485.4(GRWD1):c.1102G>T (p.Val368Phe)	Likely pathogenic

SpliceAI

1114 predictions. Top by Δscore:

Variant	Effect	Δscore
19:48446162:GCC:G	donor_gain	1.0000
19:48446188:GACTG:G	donor_gain	1.0000
19:48446499:ACAGG:A	donor_loss	1.0000
19:48446501:AGG:A	donor_loss	1.0000
19:48446504:T:G	donor_loss	1.0000
19:48446677:CCA:C	acceptor_loss	1.0000
19:48446678:CAGA:C	acceptor_loss	1.0000
19:48446679:A:AG	acceptor_gain	1.0000
19:48446679:AGAC:A	acceptor_loss	1.0000
19:48446679:AGACT:A	acceptor_gain	1.0000
19:48446680:G:GA	acceptor_gain	1.0000
19:48446680:GA:G	acceptor_gain	1.0000
19:48446680:GAC:G	acceptor_gain	1.0000
19:48446680:GACT:G	acceptor_gain	1.0000
19:48446680:GACTG:G	acceptor_gain	1.0000
19:48446839:TTCGG:T	donor_gain	1.0000
19:48446840:TCGG:T	donor_gain	1.0000
19:48446841:CGG:C	donor_gain	1.0000
19:48446841:CGGGT:C	donor_gain	1.0000
19:48446842:GG:G	donor_gain	1.0000
19:48446842:GGG:G	donor_gain	1.0000
19:48446843:GG:G	donor_gain	1.0000
19:48446843:GGTA:G	donor_loss	1.0000
19:48446844:G:GG	donor_gain	1.0000
19:48446844:GT:G	donor_loss	1.0000
19:48450307:CTGCA:C	acceptor_loss	1.0000
19:48450308:TGCAG:T	acceptor_loss	1.0000
19:48450309:GCA:G	acceptor_loss	1.0000
19:48450310:CAGGT:C	acceptor_loss	1.0000
19:48450311:A:C	acceptor_loss	1.0000

AlphaMissense

2899 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:48451181:A:C	S325R	0.999
19:48451183:T:A	S325R	0.999
19:48451183:T:G	S325R	0.999
19:48452825:T:A	W381R	0.999
19:48452825:T:C	W381R	0.999
19:48452909:T:C	F409L	0.999
19:48452911:C:A	F409L	0.999
19:48452911:C:G	F409L	0.999
19:48450496:T:C	F218L	0.998
19:48450498:T:A	F218L	0.998
19:48450498:T:G	F218L	0.998
19:48451041:C:A	A278D	0.998
19:48451073:T:A	W289R	0.998
19:48451073:T:C	W289R	0.998
19:48451076:G:C	D290H	0.998
19:48451077:A:C	D290A	0.998
19:48451077:A:T	D290V	0.998
19:48452765:T:A	W361R	0.998
19:48452765:T:C	W361R	0.998
19:48452827:G:C	W381C	0.998
19:48452827:G:T	W381C	0.998
19:48446399:A:C	S68R	0.997
19:48446401:C:A	S68R	0.997
19:48446401:C:G	S68R	0.997
19:48446471:G:T	G92W	0.997
19:48450508:T:A	W222R	0.997
19:48450508:T:C	W222R	0.997
19:48450707:T:A	W242R	0.997
19:48450707:T:C	W242R	0.997
19:48450788:T:A	W269R	0.997

dbSNP variants (sampled 300 via entrez): RS1000055611 (19:48456853 A>G,T), RS1000126016 (19:48454942 ATTTCT>A), RS1000178712 (19:48455144 A>G,T), RS1000278968 (19:48449874 G>A), RS1000430115 (19:48457139 G>C), RS1000511465 (19:48454071 C>A,T), RS1000851469 (19:48452298 A>G), RS1000915004 (19:48451744 G>A,T), RS1001012202 (19:48448662 G>T), RS1001674836 (19:48449012 G>T), RS1001945327 (19:48446231 G>C), RS1002184073 (19:48452911 C>A,G,T), RS1002235592 (19:48456491 G>A), RS1002285330 (19:48447460 G>A), RS1002408610 (19:48447624 G>A)

Disease associations

OMIM: gene MIM:610597 | disease phenotypes: MIM:214700, MIM:621160

GenCC curated gene-disease

Disease	Classification	Inheritance
congenital diarrhea	Limited	Autosomal recessive

Mondo (3): prostate cancer (MONDO:0008315), congenital diarrhea (MONDO:0000824), diarrhea 14, congenital (MONDO:0976266)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

4 total (4 of 4 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0002014	Diarrhea
HP:0003577	Congenital onset
HP:0033994	Dependency on parenteral nutrition

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5724692 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

49 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression, affects expression, decreases expression, affects cotreatment, increases abundance	3
bisphenol A	decreases expression	2
Smoke	decreases expression, increases abundance, increases expression	2
Valproic Acid	affects cotreatment, increases expression, increases methylation	2
Cadmium Chloride	decreases expression, increases abundance, increases expression	2
FR900359	increases phosphorylation	1
TAK-243	increases sumoylation	1
TL8-506	affects cotreatment, increases expression	1
cinobufagin	decreases expression	1
2,4,6-tribromophenol	decreases expression	1
deoxynivalenol	increases expression	1
decabromobiphenyl ether	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
tetrabromobisphenol A	increases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
nivalenol	increases expression	1
di-n-butylphosphoric acid	affects expression	1
cylindrospermopsin	increases expression	1
K 7174	decreases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	decreases expression	1
ICG 001	decreases expression	1
abrine	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
(+)-JQ1 compound	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Temozolomide	increases expression	1
Air Pollutants	increases abundance, increases expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Cadmium	increases abundance, increases expression	1
Caffeine	decreases phosphorylation	1

ChEMBL screening assays

6 unique, capped per target: 6 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5697358	Binding	Inhibition of GRWD1 (unknown origin) assessed as fold change at 10 uM incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. — Nature

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer